Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
Identify Which Targeting Strategies Are At Work Within Antiangiogenic Drug Developments
April 11th, 2008
Research and Markets has announced the addition of "Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology" to their offering. There is a plethora of new anti-angiogenic drugs in development. The potential to block tumour growth and metastases by angiogenesis inhibition represents an intriguing therapeutic strategy for the treatment of cancer and never before have we seen as many anti-angiogenic drugs in clinical trials. This report is written for you to identify your competition and understand which targeting strategies are at work within anti-angiogenic drug development in...
Source: Health Business Week (2008-04-11)
|
